Literature DB >> 8790413

A candidate live inactivatable attenuated vaccine for AIDS.

B K Chakrabarti1, R K Maitra, X Z Ma, H W Kestler.   

Abstract

The recent discovery of long term AIDS nonprogressors who harbor nef-attenuated HIV suggests that a naturally occurring live vaccine for AIDS may already exist. Animal models have shown that a live vaccine for AIDS, attenuated in nef, is the best candidate vaccine. There are considerable risks, real and perceived, with the use of live HIV vaccines. We have introduced a conditional lethal genetic element into HIV-1 and simian immunodeficiency virus (SIV) molecular clones deleted in nef. The antiviral strategy we employed targets both virus replication and the survival of the infected cell. The suicide gene, herpes simplex virus thymidine kinase (tk), was expressed and maintained in HIV over long periods of time. Herpes simplex virus tk confers sensitivity to the antiviral activity of acyclic nucleosides such as ganciclovir (GCV). HIV-tk and SIV-tk replication were sensitive to GCV at subtoxic concentrations, and virus-infected cells were eliminated from tumor cell lines as well as primary cell cultures. We found the HIV-tk virus to be remarkably stable even after being cultured in media containing a low concentration of GCV and then challenged with the higher dose and that while GCV resistant escape mutants did arise, a significant fraction of the virus remained sensitive to GCV.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8790413      PMCID: PMC38511          DOI: 10.1073/pnas.93.18.9810

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  49 in total

Review 1.  The enigma of HIV infection.

Authors:  D Baltimore
Journal:  Cell       Date:  1995-07-28       Impact factor: 41.582

2.  Time to hit HIV, early and hard.

Authors:  D D Ho
Journal:  N Engl J Med       Date:  1995-08-17       Impact factor: 91.245

3.  Brief report: absence of intact nef sequences in a long-term survivor with nonprogressive HIV-1 infection.

Authors:  F Kirchhoff; T C Greenough; D B Brettler; J L Sullivan; R C Desrosiers
Journal:  N Engl J Med       Date:  1995-01-26       Impact factor: 91.245

4.  Analysis of the UL97 phosphotransferase coding sequence in clinical cytomegalovirus isolates and identification of mutations conferring ganciclovir resistance.

Authors:  S Chou; A Erice; M C Jordan; G M Vercellotti; K R Michels; C L Talarico; S C Stanat; K K Biron
Journal:  J Infect Dis       Date:  1995-03       Impact factor: 5.226

5.  Clearance of HIV infection in a perinatally infected infant.

Authors:  Y J Bryson; S Pang; L S Wei; R Dickover; A Diagne; I S Chen
Journal:  N Engl J Med       Date:  1995-03-30       Impact factor: 91.245

6.  Integration is required for productive infection of monocyte-derived macrophages by human immunodeficiency virus type 1.

Authors:  G Englund; T S Theodore; E O Freed; A Engelman; M A Martin
Journal:  J Virol       Date:  1995-05       Impact factor: 5.103

7.  Pathogenicity of live, attenuated SIV after mucosal infection of neonatal macaques.

Authors:  T W Baba; Y S Jeong; D Pennick; R Bronson; M F Greene; R M Ruprecht
Journal:  Science       Date:  1995-03-24       Impact factor: 47.728

8.  A protein kinase homologue controls phosphorylation of ganciclovir in human cytomegalovirus-infected cells.

Authors:  V Sullivan; C L Talarico; S C Stanat; M Davis; D M Coen; K K Biron
Journal:  Nature       Date:  1992-07-09       Impact factor: 49.962

9.  Progression to AIDS in the absence of a gene for vpr or vpx.

Authors:  J S Gibbs; A A Lackner; S M Lang; M A Simon; P K Sehgal; M D Daniel; R C Desrosiers
Journal:  J Virol       Date:  1995-04       Impact factor: 5.103

10.  Genomic structure of an attenuated quasi species of HIV-1 from a blood transfusion donor and recipients.

Authors:  N J Deacon; A Tsykin; A Solomon; K Smith; M Ludford-Menting; D J Hooker; D A McPhee; A L Greenway; A Ellett; C Chatfield; V A Lawson; S Crowe; A Maerz; S Sonza; J Learmont; J S Sullivan; A Cunningham; D Dwyer; D Dowton; J Mills
Journal:  Science       Date:  1995-11-10       Impact factor: 47.728

View more
  3 in total

Review 1.  AIDS vaccine development: let a thousand flowers bloom.

Authors:  J S Oxford; M Addawe; R Lambkin
Journal:  J Clin Pathol       Date:  1998-10       Impact factor: 3.411

2.  Regulation of human immunodeficiency virus replication by 2',5'-oligoadenylate-dependent RNase L.

Authors:  R K Maitra; R H Silverman
Journal:  J Virol       Date:  1998-02       Impact factor: 5.103

Review 3.  Radiolabeled antiviral drugs and antibodies as virus-specific imaging probes.

Authors:  Mike Bray; Michele Di Mascio; Fabian de Kok-Mercado; Daniel J Mollura; Elaine Jagoda
Journal:  Antiviral Res       Date:  2010-08-13       Impact factor: 5.970

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.